Sarepta Therapeutics is meeting with the FDA in June to discuss expanding the use of its Duchenne muscular dystrophy gene ...

The government 'did not act contrary to the law' by requiring drugmakers to seek approval before implementing proposed new 340B rebate models, a federal judge ruled.

The FDA is prepping to renegotiate its multibillion-dollar, quinquennial user fee agreements with the drug industry later ...

American Society of Gene & Cell Therapy meeting sees 10% drop in attendance. Notable absences include FDA officials, David ...

The Trump administration is partnering with Mark Cuban’s compounding business and four other entities to improve the ...

BioMarin plans to buy Boston-based Inozyme Pharma and its Phase 3 enzyme replacement therapy for about $270 million, the ...

FDA lifts hold on Scynexis' ibrexafungerp Phase 3 fungal infection trial, but GSK plans to end study. Incyte's Zynyz gets FDA ...

Leo Pharma is doing an extensive revamp of its leadership team as it splits product strategy and international operations ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down amid market challenges and a clinical disappointment for CagriSema.

RFK Jr. advisor Calley Means challenges drugmakers considering pulling their investment in the US over Trump's most favored ...

A Delaware jury on Thursday said Regeneron should get more than $400 million in damages in its long-running antitrust case ...

The comments come just a couple months after the company slashed its 2027 sales expectations for the Biogen-partnered ...